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Abstract
Introduction: Adipose-derived stem cells (ASCs) have the potential to differentiate into cartilage under stimulation
with some reported growth and transcriptional factors, which may constitute an alternative for cartilage
replacement approaches. In this study, we analyzed the in vitro chondrogenesis of ASCs transduced with
adenoviral vectors encoding insulin-like growth factor-1 (IGF-1), transforming growth factor beta-1 (TGF-b1),
fibroblast growth factor-2 (FGF-2), and sex-determining region Y-box 9 (SOX9) either alone or in combinations.
Methods: Aggregate cultures of characterized ovine ASCs were transduced with 100 multiplicity of infections of
Ad.IGF-1, Ad.TGF-b1, Ad.FGF-2, and Ad.SOX9 alone or in combination. These were harvested at various time points
for detection of cartilage-specific genes expression by quantitative real-time PCR or after 14 and 28 days for
histologic and biochemical analyses detecting proteoglycans, collagens (II, I and X), and total sulfated
glycosaminoglycan and collagen content, respectively.
Results: Expression analyses showed that co-expression of IGF-1 and FGF-2 resulted in higher significant expression
levels of aggrecan, biglycan, cartilage matrix, proteoglycan, and collagen II (all P ≤0.001 at 28 days). Aggregates co-
transduced with Ad.IGF-1/Ad.FGF-2 showed a selective expression of proteoglycans and collagen II, with limited
expression of collagens I and × demonstrated by histological analyses, and had significantly greater
glycosaminoglycan and collagen production than the positive control (P ≤0.001). Western blot analyses for this
combination also demonstrated increased expression of collagen II, while expression of collagens I and × was
undetectable and limited, respectively.
Conclusion: Combined overexpression of IGF-1/FGF-2 within ASCs enhances their chondrogenic differentiation
inducing the expression of chondrogenic markers, suggesting that this combination is more beneficial than the
other factors tested for the development of cell-based therapies for cartilage repair.
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Introduction
Articular cartilage is a highly specialized connective tis-
sue with a unique architecture that enables almost fric-
tionless articulation of joint surfaces and the ability to
absorb mechanical stress. Although remarkably durable,
articular cartilage has a restricted capacity for intrinsic
regeneration, and even minor injuries may lead to pro-
gressive damage and subsequent join degeneration [1,2].
Adult mesenchymal stem cells (MSCs) present a viable
alternative for primary differentiated chondrocytes that
must be isolated from very limited sources of cells and
are difficult to expand ex vivo [3,4]. Adipose-derived
stem cells (ASCs) have been shown to possess multiline-
age differentiation potential into osteogenic, chondro-
genic, adipogenic, myogenic, neurogenic, and endothelial
cells in the presence of lineage-specific induction factors,
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and have been characterized extensively for chondrogen-
esis [5,6]. ASCs are abundant in fat tissues and are rela-
tively easy to obtain and expand in culture. These cells
exhibit low rates of senescence, even after nine or more
passages [7,8].
In vitro chondrogenesis of ASCs is a finely regulated
process that requires appropriate expanded monolayer
conditions and subsequent high-density culture in speci-
fic media supplements and growth factor-containing
medium. Potentially useful growth factors are members
of the transforming growth factor beta (TGF-b) super-
family, including TGF-b1, TGF-b2 and TGF-b3, several
bone morphogenic proteins, insulin-like growth factor-1
(IGF-1), fibroblast growth factors, and epidermal growth
factor, among others [9]. Numerous studies have shown
that co-administration of TGF-b1 and IGF-1 efficiently
stimulates chondrogenic differentiation and increase
matrix synthesis of chondrogenic cells [10-12]. In vivo
co-administration of IGF-1 and FGF-2 has also been
reported to accelerate articular cartilage repair [13], while
administration of FGF-2 in the presence of TGF-b1 sig-
nificantly enhances cell proliferation, which results in
increased neocartilage formation at later stages [14].
Another class of biologics that promote chondrogen-
esis are the transcription factors sex-determining region
Y-box 9 (SOX9) and related L-SOX5 and SOX6. These
factors have been identified as essential factors for chon-
drocyte differentiation and cartilage formation [15].
However, the short half-lives of recombinant proteins,
and a lack of effective delivery methods for intracellular
signaling, challenge the clinical uses of these factors.
Gene transfer offers an alternative approach to protein
delivery that may satisfactorily overcome the limitations
of conventional methods [9,16,17]. Viral vectors can be
used to deliver cDNAs that code for therapeutic proteins
to specific target cells, and the genetically modified cell is
converted in a biofactory for protein production [18].
Sustained protein synthesis can be concentrated at the
site of injury by in situ gene delivery with minimal collat-
eral exposure of nontarget tissues [16].
The effectiveness of several growth-factor combinations
for chondrogenic differentiation of ASCs is still unclear.
Methods to effectively stimulate proliferation and chon-
drogenic differentiation of ASCs are needed to further
develop the use of these cells for cartilage repair. The
effects of expression of adenoviral vectors carrying IGF-1,
TGF-b1, FGF-2 and SOX9 cDNAs on chondrogenesis of
primary ASCs in vitro, using single vectors and/or their
combinations, were also evaluated in this study.
Materials and methods
Preparation of recombinant adenoviral vectors
First-generation, E1, E3-deleted, serotype 5 adenoviral
vectors carrying the cDNAs for GFP, human IGF-1,
human TGF-b1, human FGF-2, and human SOX9 were
constructed using the method of Luo and colleagues
[19]. The resulting vectors were designated Ad.GFP, Ad.
IGF-1, Ad.TGF-b1, Ad.FGF-2, and Ad.SOX9, respec-
tively. To generate high-titer preparations, the recombi-
nant vectors were amplified in HEK-293 cells and
purified over three successive cesium chloride gradients.
Following dialysis against 10 mM Tris-hydrochloric acid,
pH 7.4, 150 mM sodium chloride, 10 mM magnesium
chloride, and 4% sucrose, the preparations were aliquoted
and stored at -80°C. Viral titers were estimated by optical
density (at 260 nm) and median tissue culture infectious
dose methods. Using these methods, preparations of 107
to 109 plaque-forming units/ml were obtained
Adipose-derived stem cell isolation, culture and
characterization
The protocol involving research in animals was
approved by the UANL School of Medicine & University
Hospital Institutional Review Board (reference number:
BI12-002) and experiments were conducted following
the Mexican ordinances for the treatment of experimen-
tal animals (Norma Oficial Mexicana 062-ZOO-1999).
ASCs were harvested from the adipose tissue of one
6-month-old Ovis aries weighing 37.4785 lb, and 0.5 g
adipose tissue biopsy specimens were digested with
800 µl collagenase I (180 U/ml) solution using the proto-
col of Dubois and colleagues [20]. The collected cells
were pelleted using centrifugation at 1,500 rpm for 10
minutes, and resuspended in DMEM containing 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin/
amphotericin B (all Invitrogen, Carlsbad, CA, USA). The
cells were plated in a 75 cm2 tissue culture flask (Falcon,
Beckton Dickinson Labware, Franklin Lakes, NJ, USA).
Nonadherent cells were removed after 3 days; the
remaining attached cells were washed with PBS and cul-
tured in DMEM with 10% FBS at 37°C, 5% CO2 with
medium changes every 3 days. After 10 to 15 days, adher-
ent colonies of cells were trypsinized and replated in sev-
eral 75 cm2 tissue culture flasks, six-well or 96-well
plates depending on the procedure.
To confirm the ASC phenotype, cell cultures were
characterized through immunophenotype and RT-PCR.
Flow cytometry was performed on a FACScan argon
laser cytometer (Becton Dickson, San Jose, CA, USA).
Cells were harvested in 0.25% trypsin/ethylenediaminete-
traacetic acid and fixed for 30 minutes in ice-cold 2% for-
maldehyde. Following fixation, cells were washed in flow
cytometry buffer (1 × PBS, 2% FBS, 0.2% Tween-20). Cell
aliquots (1 ×106 cells) were incubated in flow cytometry
buffer containing the following mAbs: anti-CD271-PE,
anti-CD45-FITC and anti-mesenchymal stromal cell anti-
gen-1-APC (all AbD Serotec, Kidlington, UK). In addi-
tion, RNA was isolated from primary ASC cultures
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according to the TRIzol® Reagent protocol (Invitrogen).
cDNA was synthesized from total RNA using the Super-
Script™ III First-Strand Synthesis SuperMix and random
hexamers (Invitrogen). One hundred nanograms of
cDNA synthesized were used as templates for PCR
amplification in a 25 µl reaction volume using Taq DNA
polymerase (Promega, Madison, WI, USA) and 500 nM
gene-specific primers. Amplifications were performed for
35 cycles, and RT-PCR products were visualized on 2%
agarose gels containing 0.1 µg/ml ethidium bromide. The
primer sequences and product sizes for CD34, CD73,
CD90, CD105, CD166, CD45, CD117, CD271, CD14, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
are listed in Additional file 1.
Cell viability assay
ASCs were seeded into 96-well plates and grown to 80%
confluence, generating approximately 2.6 × 104 cells/
well. Individual wells of cells, in triplicate, were trans-
duced in 100 µl serum-free DMEM for 2 hours with
decreasing doses (1,000, 100, 10 and 1 multiplicity of
infections (MOIs)) of individual Ad.GFP, Ad.IGF-1, Ad.
TGF-b1, Ad.FGF-2, and Ad.SOX9 vectors or combina-
tions (Ad.IGF-1/Ad.TGF-b1, Ad.IGF-1/Ad.FGF-2, Ad.
IGF-1/Ad.TGF-b1/Ad.SOX9, and Ad.IGF-1/Ad.FGF-2/
Ad.SOX9). Following transduction, the culture fluids were
aspirated and replaced with 200 µl DMEM containing 2%
FBS and 1% penicillin/streptomycin/amphotericin B. In
parallel, control nontransduced cultures were maintained
in the same medium. Cells were incubated at 37°C, 5%
CO2 for 10 days, and then viability was measured accord-
ing to the Alamar Blue® protocol (Invitrogen).
Adenoviral transduction of adipose-derived stem cells in
monolayers
Following the initial plating, the adherent cultures of
ASCs were seeded into six-well plates and grown to
80% confluence, generating approximately 7.6 × 105
cells/well. Individual wells of cells, in triplicate, were
transduced in 800 µl serum-free DMEM for 2 hours
with 100 MOIs of Ad.IGF-1, Ad.TGF-b1, Ad.FGF-2 and
Ad.SOX9 alone or in combination (Ad.IGF-1/Ad.TGF-
b1, Ad.IGF-1/Ad.FGF-2, Ad.IGF-1/Ad.TGF-b1/Ad.SOX9
and Ad.IGF-1/Ad.FGF-2/Ad.SOX9), using 50 + 50
MOIs by two vectors or 33.3 + 33.3 + 33.3 MOIs by
three vectors (100 MOIs together), respectively. Nega-
tive control cultures were similarly transduced with Ad.
GFP.
Following transduction, the culture fluids were aspi-
rated and replaced with 2 ml DMEM containing 25 mM
glucose, 6.25 µg/ml insulin-transferrin-sodium selenite,
5.33 µg/ml linoleic acid, 1.25 mg/ml BSA, 100 nM dexa-
methasone, 50 µg/ml L-ascorbic-2-phosphate, 2 mM
sodium pyruvate, 40 µg/ml L-proline (all Sigma-Aldrich,
St Louis, MO, USA), 10% FBS and 1% penicillin/strepto-
mycin/amphotericin B. In parallel, non-transduced cul-
tures (positive control), were replaced with 2 ml HyClone
AdvanceSTEM Chondrogenic Differentiation Medium
(Thermo Scientific, Rockford, IL, USA). The cells were
cultured at 37°C, 5% CO2 and began to form spherical
aggregates after 3 days of culture, excepting the negative
control that was maintained in a monolayer. Media were
changed every 3 days. Cultures were harvested at various
time points for quantitative real time (qRT)-PCR analyses
or after 14 days for histologic and biochemical analyses.
Ad.GFP transduced cultures were viewed for fluores-
cence at 72 hours following transduction.
Quantitative real time PCR assay
qRT-PCR was used to evaluate quantitatively transcrip-
tion both transgene expression and cartilage-specific
genes following transduction of ASCs with 100 MOIs of
Ad.IGF-1, Ad.TGF-b1, Ad.FGF-2 and Ad.SOX9 alone or
in combination (Ad.IGF-1/Ad.TGF-b1, Ad.IGF-1/Ad.
FGF-2, Ad.IGF-1/Ad.TGF-b1/Ad.SOX9 and Ad.IGF-1/
Ad.FGF-2/Ad.SOX9), respectively. Total RNA was iso-
lated from each triplicate group of ASCs grown in
monolayer or aggregates cultured per time points (0, 3,
14, and 28 days), using TRIzol® Reagent (Invitrogen).
cDNA was synthesized from total RNA using Super-
Script™ III First-Strand Synthesis SuperMix and ran-
dom hexamers (Invitrogen).
qRT-PCR was performed using a CFX96 real-time
PCR detection system (Bio-Rad, Hercules, CA, USA) in
96-well PCR plates. Twenty nanograms of synthesized
cDNA were used as templates for qRT-PCR amplifica-
tion in a 15 µl final reaction volume using 1 × iQ™
SYBR® Green Supermix (Bio-Rad), and 500 nM gene-
specific primers, which were designed based on the
respective GenBank sequence for the examined gene.
Amplifications were performed with the following ther-
mal cycle program: predenaturation for 10 minutes at
95°C, PCR amplification for 40 cycles of denaturizing
for 15 seconds at 95°C, and annealing for 1 minute at
60°C. Cycle series were followed by melt-curve analyses
to check the specificity of the reaction. Sequences and
product sizes of forward and reverse primers for aggre-
can (AGC), biglycan (BGC), cartilage matrix (CM), col-
lagen I (COL I), collagen II (COL II), collagen × (COL
X), proteoglycan (PGC), IGF-1, TGF-b1, FGF-2, SOX9,
and GAPDH are listed in Additional file 1. The effi-
ciency and specificity of each primer set was confirmed
with standard curve and melting profile evaluation; the
efficiency of amplification relative to GAPDH gene was
confirmed with standard curve; all this accords with a
standardization reported before [21].
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Aggregate culture and protein expression
Following the initial plating, the adherent cultures of
ASCs were seeded into six-well plates and grown to 80%
confluence, generating approximately 7.6 × 105 cells/well.
Individual wells of cells, in triplicate, were transduced in
800 µl serum-free DMEM for 2 hours with 100 MOIs of
Ad.IGF-1, and Ad.FGF-2 alone or in combination.
Following transduction, the culture fluids were aspirated
and replaced with 2 ml DMEM containing 25 mM
glucose, 6.25 µg/ml insulin-transferrin-sodium selenite,
5.33 µg/ml linoleic acid, 1.25 mg/ml BSA, 100 nM dexa-
methasone, 50 µg/ml L-ascorbic-2-phosphate, 2 mM
sodium pyruvate, 40 µg/ml L-proline (all Sigma-Aldrich,
St Louis, MO, USA), 10% FBS and 1% penicillin/strepto-
mycin/amphotericin B. The cells were cultured at 37°C,
5% CO2 and began to form spherical aggregates after
3 days of culture. Media were collected and changed at 3,
7, 14, and 21 days, and the aggregates were harvested at
14 and 28 days for ELISA analyses for the respective
growth factors using the appropriate commercially avail-
able ELISA kits (Abcam Inc., Cambridge, MA, USA) for
human IGF-1 and FGF-2.
Biochemical analysis
Three aggregates per group, cultured for 28 days, were
digested for 18 hours at 65°C by incubating them in 1
ml papain solution containing 125 µg/ml papain with
5 mM L-cysteine-HCl and 5 mM ethylenediaminetetraa-
cetic acid in 100 mM sodium phosphate monobasic (pH
6.2). The total sulfated glycosaminoglycan (GAG) con-
tent was determined using shark chondroitin sulfate as
the standard and measuring the sample content with the
1,9-dimethylmethylene blue assay. The total collagen
content was determined by measuring the hydroxypro-
line content of the aggregates after acid hydrolysis and
reaction with p-dimethylaminobenzaldehyde and chlora-
mine-T, using 0.134 as the ratio of hydroxyproline to
collagen (all Sigma-Aldrich). Both the total collagen
content and GAG content were normalized to the total
DNA content, which was measured fluorometrically using
the Hoechst 33258 dye (bisbenzimide) DNA quantitation
kit according to the manufacturer’s protocol (excitation
wavelength, 485 nm; emission wavelength, 535 nm; Bio-
Rad). The DNA concentration was determined from a
standard curve of calf thymus DNA (Bio-Rad).
Histological and immunohistochemical analysis
Before tissue processing, representative aggregates of
each group were photographed using a digital camera
(Model C653; Kodak, Rochester, NY, USA). For histolo-
gical analyses, aggregates cultured for 14 and 28 days
were embedded in Tissue-Tek® O.C.T™ Compound
(Sakura Finetek, Torrance, CA, USA) to ease handling,
and then sectioned to 10 µm in thickness at -20°C using
a Tissue-Tek cryostat (Model 4553; Miles Inc., Elkhart,
IN, USA). Representative sections were stained using
toluidine blue for the detection of matrix proteoglycan,
and safranine-O/fast green staining for the detection of
accumulation of sulfated proteoglycans (all Sigma-
Aldrich).
For immunohistochemistry, sections of aggregates cul-
tured for 28 days prepared as described above were rinsed
with PBS and treated sequentially with 30% (vol/vol)
H2O2/methanol at a ratio of 1:9 for 10 minutes, and 0.15%
TritonX-100 in 1 × PBS for 10 minutes. Sections were
then blocked with 5% BSA in PBS for 30 minutes. After-
wards, the sections were incubated overnight at 4°C with
mouse monoclonal anti-COL I and anti-COL II primary
antibodies (all Abcam Inc.) and mouse monoclonal anti-
COL × (Sigma-Aldrich) diluted in 1% BSA in PBS. After
three PBS washes to remove unbound primary antibody,
sections were incubated with a biotinylated secondary
antibody against mouse IgG for 1 hour and peroxidase-
conjugated streptavidin solution for 30 minutes at room
temperature (both DakoCytomation, Carpinteria, CA,
USA). The slides were washed again and mounted in
Fluoromount-G™ (SouthernBiotech, Birmingham, AL,
USA), and coverslipped for microscopic observation
(Model E600; Nikon Corporation, Tokyo, Japan). The
negative control consisted of monolayer ASCs cultured in
incomplete chondrogenic medium, fixed, and immunos-
tained in situ. For each experiment described, three repli-
cates were performed, with three aggregates for each
group.
Western blot analysis and densitometry
Approximately 3 × 106 ASCs per 75 cm2 plate were
transduced with Ad.IGF-1/Ad.FGF-2 (50 MOIs each),
were nontransduced but stimulated with HyClone
AdvanceSTEM Chondrogenic Differentiation Medium
(Thermo Scientific) (positive control), and were not
transduced and non-stimulated ASCs grown in DMEM
(negative control). Total protein extract was obtained at
28 days post transduction. COL I, COL II, and COL ×
were detected by western blot analysis at day 28. Briefly,
50 µg total protein extract in Laemmli buffer was sub-
jected to 10% SDS-PAGE and transferred to a nitrocel-
lulose membrane; blocking was performed with nonfat
milk 5% in Tris-buffered saline with Tween GAPDH
was detected as a sample loading control using a pri-
mary rabbit polyclonal anti-human GAPDH (dilution
1:5,000; Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) and a horseradish peroxidase conjugated with
goat anti-rabbit IgG antibodies (dilution 1:5,000; Santa
Cruz Biotechnology Inc.). Primary rabbit polyclonal
anti-human type I, II and × collagen (dilution 1:3,000;
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Abcam) were used to detect COL I, COL II, and COL
X, respectively. Bound antibodies were detected with
horseradish peroxidase conjugated with goat anti-rabbit
IgG antibodies (1:5,000; Abcam). A densitometric analy-
sis using GAPDH expression for assay normalization
was performed (Phoretix 1D software; TotalLab Ltd,
Newcastle, UK).
Statistical analysis
Data from the cell viability assay, qRT-PCR and bio-
chemical assays were analyzed for statistical significance
between two comparative specimens by a Student t test
or Mann-Whitney U test according to data distribution
normality, using SigmaPlot v11.0 (Systat Software Inc.,
San Jose, CA, USA). Data are presented as mean ± stan-
dard deviation. Differences were considered of statistical
significance when P <0.05.
Results
Phenotypic characterization of adipose-derived stem cells
First-passage cells were characterized through stem cell
marker detection using immunophenotype by flow cyto-
metry and RT-PCR. The immunophenotype showed
that the expression of CD271, mesenchymal stromal cell
antigen-1 and CD45 were 85.82%, 95.55% and 36.78%,
respectively. RT-PCR showed amplification for CD73,
CD90, CD14, CD166, CD105, CD271, and GAPDH, and
no amplification for CD34, CD45, and CD117. This
expression profile is typical for ASCs except for CD45
and CD14. Phenotypic characterizations are summarized
in Table 1[22,23]. In general, these results demonstrated
successful ASC isolation.
Cell viability and transduction efficiency of adipose-
derived stem cells with adenoviral vectors
To determine the adenoviral concentration at which
adherent ASCs can be genetically modified with one,
two or three anabolic transgenes in high-density culture
without compromising their viability, first-passage
monolayer cultures were transduced with recombinant
Ad.IGF-1, Ad.TGF-b1, Ad.FGF-2, or Ad.SOX9 alone or
in combination at total viral doses of 1, 10, 100 or 1,000
MOIs, as indicated in Materials and methods; vector
combinations were performed at 1:1 and 1:1:1 ratios for
combination of two and three vectors, respectively. Con-
trol groups consisted of naive and transduced ASC cul-
tures with equivalent doses of adenoviral vectors
encoding Ad.GFP. First-passage monolayer cultures
were also transduced with the same increasing amounts
of Ad.GFP to provide a relative comparison for trans-
duction efficiency. After 72 hours and consistent with
the ASC cultures, GFP-positive cells appeared with the
typical fibroblast-like morphology. One hundred MOIs
were selected to transduce ASCs due to the high level
of transduction (>90%) and >80% cell viability (see
Additional file 2).
Chondrogenic differentiation of adipose-derived stem
cells after adenoviral delivery of IGF-1, TGF-b1, FGF-2 and
SOX9 alone or in combination
To determine the relative level of transgene expressed,
parallel cultures of ASCs were transduced with 100
MOIs of Ad.IGF-1, Ad.TGFb-1, Ad.FGF-2, and Ad.
SOX9, both in single and combined transductions. For
each experimental group, transgene expression was
decreasing through time (3, 7, 14, 21 and 28 days;
Figure 1A). Because primary ASCs were shown to be
able of sustained expression of different anabolic trans-
genes after adenoviral-mediated transduction (see Addi-
tional file 3), the effects of growth factor co-expression
on in vitro chondrogenesis of ASC aggregates were ana-
lyzed. Second-passage monolayer cultures of ASCs (7.6 ×
105 ASCs) were transduced in triplicate with 100 MOIs of
Ad.IGF-1, Ad.TGFb-1, Ad.FGF-2, and Ad.SOX9, both in
single and combined transductions. Following transduc-
tion, the culture fluids were aspirated and replaced with a
defined supplemented medium. The cells began to form
spherical aggregates after 3 days of culture; they were
maintained for 28 days, being harvested at 14 and 28 days
to be analyzed.
Histological examination indicated evidence of trans-
gene-induced chondrogenesis of the ASCs. Aggregates
receiving Ad.FGF-2 together with Ad.IGF-1 had greater
chondrogenic response than aggregates receiving the
adenovirus alone (Ad.IGF-1, Ad.TGF-b1, Ad.FGF-2, Ad.
SOX9) or in other combinations (Ad.IGF-1/Ad.TGF-b1,
Table 1 Phenotypic characterization of adipose-derived
stem cells through immunophenotype and RT-PCR
Analyzed marker Immunophenotypea RT-PCRb
Positivec
CD73 NT ++
CD90 NT ++
CD105 NT ++
CD166 NT ++
CD271 ++ ++
MSCA ++ NT
Negativec
CD14 NT +
CD34 NT -
CD45 + -
CD117 NT -
GAPDHd NT ++
aNT, not tested; +, positive (≤50%); ++, positive (≥85%). bNT, not tested; -,
negative; +, positive (faint band); ++, positive (intense band). cExpected result
of surface antigen expression on mesenchymal stem cells according to the
literature [22,23]. dHousekeeping gene.
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Ad.IGF-1/Ad.TGF-b1/Ad.SOX9, Ad.IGF-1/Ad.FGF-2/
Ad.SOX9). This response was demonstrated by the pro-
duction of COL II and proteoglycans (Figure 2).
Co-delivery of IGF-1 and FGF-2 led to larger aggregate
size, greater cellularity, and greater deposition of proteo-
glycan at days 14 and 28, as indicated by Safranin-O/
fast green and toluidine blue, which displayed the spatial
organization of the negatively charged proteoglycan with
Figure 1 Gene expression in genetically modified adipose-derived stem cells aggregate cultures. Adipose-derived stem cells (ASCs) were
transduced with 100 multiplicity of infections of respective adenoviral vectors as indicated, cultured into aggregates, and maintained in a
defined serum-free medium for 3, 7, 14, 21 or 28 days. For each treatment group and time point indicated, RNA was extracted from three
aggregates, and both expression of (A) tranduced genes (3, 7, 14, 21 and 28 days) and (B,C,D,E,F,G,H) the cartilage-specific marker genes
aggrecan (AGC), biglycan (BGC), cartilage matrix (CM), and proteoglycan (PGC), collagen (COL) I, COL II, COL X, (3, 14, and 28 days) were
determined by quantitative real time (qRT)-PCR. RNA isolated from ASCs differentiated by a commercial established medium and RNA extracted
immediately from ASCs newly transduced (time 0) were used as comparative controls. The primer sequences, product sizes, and annealing
temperatures for qRT-PCR are listed in Additional file 1. The expression level of each targeted gene was normalized to the housekeeping gene
GAPDH. Values are expressed as the fold induction of means ± standard deviations of normalized expression levels. Statistical differences
between groups and positive control were analyzed using a t test; *differences were considered significant when P <0.05. FGF-2, fibroblast
growth factor-2; IGF-1, insulin-like growth factor-1; SOX9, sex-determining region Y-box 9; TGFb, transforming growth factor beta.
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Figure 2 Chondrogenesis of adipose-derived stem cells following adenoviral-mediated gene transfer. Monolayer cultures of adipose-
derived stem cells (ASCs) were transduced with 100 multiplicity of infections of Ad.IGF-1, Ad.TGF-b1, Ad.FGF-2 and Ad.SOX9 single or in
combination; following aggregate formation, the aggregates were cultured for 28 days and harvested at 14 and 28 days. Non-transduced
positive and negative control ASCs were cultured in parallel. Safranine-O and Toluidine blue stainings were used for the detection of matrix
proteoglycan in representative aggregate sections, and immunostaining was used for the presence of collagens; predominant collagen (COL) II
indicates a chondrocyte-like phenotype, predominant COL I indicates a fibrous matrix, and predominant COL × indicates hypertrophic
chondrocytes undergoing terminal differentiation. Negative control for the stainings corresponds to ASCs cultured in incomplete chondrogenic
medium. All 100 × magnification, bar = 200 µm. FGF-2, fibroblast growth factor-2; IGF-1, insulin-like growth factor-1; SOX9, sex-determining
region Y-box 9; TGFb, transforming growth factor beta.
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an orange to red hue and with a violet/red purple hue,
respectively. Figure 2 shows the production of COL II
(indicated by a prominent and uniform immunostaining
in the aggregate) characteristic of cartilage matrix and
indicator of chondrocyte-like phenotype; even a low but
detectable immunostaining for COL I indicated a fibrous
matrix related with ossification. The presence of COL X,
a marker of hypertrophic chondrocytes undergoing
terminal differentiation, was observed (Figure 2). A
green tone was appreciated in the safranin-O staining at
28 days in the other groups tested, indicating that there
is no detectable cartilage. Although phenotypic evidence
of chondrogenesis was not greater in the other tested
groups, the aggregates transduced with Ad.TGF-b1
showed a prominent inmmunostaining for COL II, pri-
marily pericellular, and low immunostaining for COL I,
making it an interesting candidate; it even showed a
prominent immunostaining for COL X. No greater dif-
ferences in immunostainings were noticed between the
aggregates co-transduced with Ad.FGF-2 and Ad.IGF-1
and positive control. The qualitative nature of the test,
however, did not allow proper statistical analysis.
Time course of chondrocyte marker gene expression
To further examine the apparent synergistic effects of
co-delivery of IGF-1 with FGF-2 in the aggregate cul-
tures, the temporal expression profiles of genes asso-
ciated with chondrogenic and osteogenic differentiation
were analyzed. At days 3, 14, and 28, aggregates (n = 3)
from each group (alone or in combination) were har-
vested, pooled, and analyzed using qRT-PCR (Figure 1B,
C,D,E,F,G,H). Aggregate cultures of ASCs differentiated
to chondrocytes by a commercial established medium
and monolayer culture of newly transduced ASCs (time
0) were used as controls. Consistent with the preceding
analyses, all of the aggregate cultures tested showed evi-
dence of chondrogenic differentiation at the RNA level.
The difference was seen from early time points, particu-
larly at day 3, when the aggregates receiving Ad.FGF-2
and Ad.IGF-1 showed significant earlier onset of expres-
sion of AGC, BGC, CM, PGC and COL II with respect
to the positive control (P = 0.012, P = 0.005, P <0.001,
P = 0.006 and P = 0.958, respectively), and they main-
tained their significant values at high levels at all time
points, being most remarkable at day 28. Even though
the aggregates transduced with Ad.FGF-2/Ad.IGF-1
were also significant in their expression for COL I at
day 3, this steadily decreased thereafter and was lower
than in the other groups when expressed at day 28,
excepting the aggregates transduced with Ad.FGF-2
alone. In addition, the expression of COL × mRNA in
the Ad.IGF-1/Ad.FGF-2 group was very similar to the
positive control with only greater expression at day 14
of culture.
Other aggregate cultures that showed strong evidence
of chondrogenic differentiation at the RNA level were
those transduced with Ad.IGF-1 or co-transduced with
Ad.IGF-1/Ad.TGF-b1, Ad.SOX9/Ad.IGF-1/Ad.TGF-b1,
and Ad.SOX9/Ad.IGF-1/Ad.FGF-2. These groups
showed not only a maintained high expression of AGC,
BGC, CM, PGC and COL II, but also a markedly main-
tained high expression of COL I and COL X. To con-
firm immunohistochemistry and qRT-PCR results,
western blot assays for COL I, COL II, and COL ×
detection in Ad.IGF-1/Ad.FGF-2 transduced ASCs at
day 28 post transduction were performed. Densitometric
analyses also demonstrated increased expression of COL
II (threefold increased compared with the positive con-
trol), while expression of COL I and COL × was unde-
tectable and limited, respectively (Figure 3). Answer: OK
Our results suggest that IGF-1/FGF-2 co-expression
accelerates and enhances the process of chondrogenesis.
Biochemical assays for the content of DNA,
glycosaminoglycans and collagen
Representative aggregates from three aggregates per group
are presented in Figure 4A,B. Aggregates co-transduced
with Ad.IGF-1/Ad.FGF-2 were larger than the other
groups and the positive control; even the aggregate trans-
duced with Ad.IGF-1 was close to the millimeter size
and was more uniform in shape. Evaluation of protein
expression from individual and Ad.IGF-1/Ad.FGF-2 co-
transduced aggregates showed a sustained transgene pro-
duction at 14 and 28 days both alone and in combination
(P >0.05). To quantitatively compare extracellular matrix
synthesis between treatment groups, GAG and collagen
levels in the aggregates after 28 days in culture were deter-
mined and normalized to DNA content. All aggregates co-
transduced with Ad.IGF-1/Ad.FGF-2 showed significantly
greater GAG and collagen production than the positive
control (P <0.001). Furthermore, this group (Ad.IGF-1/Ad.
FGF-2) showed more DNA (number of cells), GAG
and collagen content (28.438 ± 0.943, 46.064 ± 0.587
and 72.744 ± 0.005, respectively) than the other groups
(Figure 4C). Cultures transduced with Ad.GFP cultured in
incomplete chondrogenic medium [24] did not form aggre-
gates, and showed no phenotypic evidence of chondrogen-
esis. These findings correspond with the respective
aggregate sizes and correlate with the respective histological
and immunohistochemical findings (Figures 2 and 4A,B).
Discussion
Previous studies have shown that primary MSCs undergo
chondrogenesis after genetic modification with known
chondrogenic factors as TGF-b2, bone morphogenic pro-
tein-2, IGF-1, and TGF-b1 and by induction of SOX9
expression in aggregate cultures in vitro and its applica-
tion in articular cartilage repair in vivo [25-28]. In the
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present study, we adapted the ovine ASC aggregate cul-
ture system to determine whether adenoviral delivery of
single and multiple growth and transcriptional factor
genes can lead to efficient chondrogenesis in vitro.
We started by implementing some assays to character-
ize the ovine ASCs, since there are no commercially
available reagents to study surface protein markers of
this type of cell. Immunophenotype and qRT-PCR
assays performed to first-passage of ASCs isolated
showed high expression of mesenchymal stromal cell
antigen-1, CD73, CD90, CD166, CD105, and CD271,
low expression of CD14 and CD45, and lack of expres-
sion of CD34 and CD117, respectively. The low amplifi-
cation of CD14 (considered a negative marker for ASCs)
could be explained by the presence of other adherent
cells (fibroblast, stromal, or monocytes), and/or lympho-
cytes and leucocytes not completely removed from the
primary culture [29]. Immunophenotyping also showed
a low percentage of CD45, which was decreasing along
the subsequent passages as demonstrated by qRT-PCR
assay (data not shown), a behavior that has been pre-
viously described in ASCs [30]. These results demon-
strate successful ASC isolation and we report here a
more complete ASC characterization method for this
species.
Chondrogenesis differentiation of ASCs transduced
with the different candidate growth and transcriptional
factors was made using pellet culture to mimic the cel-
lular condensation process during hyaline cartilage for-
mation, with high spatial cell density and cell-cell
contact, and is therefore often used as a method for
understanding how the interaction of cells, growth fac-
tors, and environment promote a chondrogenic pheno-
type [24]. In this sense, we successfully optimized the
Figure 3 Western blot and densitometry analysis. (A) Western blot analyses at day 28 post transduction for in vitro expression of collagen
(COL) I, COL II and COL X. (B) Densitometric analysis illustrating COL/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression ratio
(Phoretix 1D software; TotalLab Ltd, Newcastle, UK). Adipose-derived stem cells (ASCs) transduced with Ad.IGF-1/Ad.FGF-2 (multiplicity of
infection 50 for each vector) showed almost threefold increased expression of COL II compared with the positive control. Similar low expressions
of COL × were observed in adenoviral transduced ASCs and the positive control. Expression of COL I was undetected in the experimental
groups. FGF-2, fibroblast growth factor-2; IGF-1, insulin-like growth factor-1; WB, positive control for type I collagen from cultured osteoblasts.
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traditional method for pellet culture preparation. To
promote aggregate formation, we seeded the cells
directly in a six-well plate, without trypsinizing the cells,
and centrifuged them into 15 ml polypropylene conical
tubes; we changed the medium for the corresponding
chondrogenic medium and incubated the cells in appro-
priate conditions. After 3 days, spherical aggregates were
formed alone. This modified method is easier, saves
material and reagents, minimizes handling, and is com-
patible with ASC chondrogenesis.
In the present study, we demonstrate that combined
overexpression of IGF-1 and FGF-2 within ASCs via
adenoviral mediated-gene transfer significantly enhanced
the chondrogenic differentiation after 28 days in an
aggregate culture system in vitro, greater than with IGF-
1, FGF-2, TGF-b1, SOX9 alone or in other combination.
While previous studies have analyzed the effects of
these factors on chondrogenesis using MSCs [6] or car-
tilage repair using chondrocytes [31,32], there has been
no study assessing combination of all of these growth
and transcriptional factors on chondrogenesis using
ASCs.
The effects of growth factor co-expression on in vitro
chondrogenesis of ASC aggregates through histologic
examination indicated that aggregates receiving Ad.FGF-2
together with Ad.IGF-1 had greater matrix production
than the other groups and control groups. The co-delivery
of these growth factors led to larger aggregate size, greater
cellularity, and greater deposition of proteoglycan.
Although the production of COL II was prominent in the
aggregates, the expression of COL × was also observed,
suggesting the presence of hypertrophic chondrocytes
undergoing terminal differentiation.
Aggregates transduced with TGF-b1 showed a promi-
nent immunostaining for COL II, predominantly in the
pericellular area, and low immunostaining for COL I,
but they also showed increased expression of COL X.
These findings are consistent with several previous stu-
dies of growth factor effects on MSC and ASC chondro-
genesis, where TGF-b1 controls the production of
extracellular matrices by stimulating the expression of
AGC and collagens, and synthesis of COL II and COL
X, which were secreted more strongly by MSCs than by
ASCs [33,34].
Although the chondrogenic effects of TGF-b1 are well
characterized, the effects of FGF-2 and IGF-1 are less
well established. IGF-1 modulates MSC chondrogenesis
by stimulating and increasing cell proliferation, regulates
cell apoptosis, and induces in vitro expression of chon-
drocyte markers as proteoglycans and COL II [35,36].
Figure 4 Size and shape of aggregates and biochemical analyses. Gross images of representative aggregates of each studied group are
presented. (A) Aggregates transduced with single adenoviral vectors correspond to positive controls (a) and (b), Ad.SOX9 (c), Ad.FGF-2 (d), Ad.
TGF-b1 (e), and AD.IGF-1 (f). (B) Aggregates transduced with combined adenoviral vectors correspond to positive controls (g) and (h), Ad.IGF-1/
Ad.TGF-b1 (i), Ad.IGF-1/Ad.FGF-2 (j), Ad.SOX9/Ad.IGF-1/Ad.TGF-b1 (k) and, Ad.SOX9/Ad.IGF-1/Ad.FGF-2 (l). (C) Biochemical analyses of in vitro
aggregates for total content of DNA, glycosaminoglycans (GAGs) and collagen. Aggregates were papain-digested and analyzed for total content
of DNA, sulfated GAGs, and synthesized collagen. The content of GAGs and collagen were normalized by the DNA content of each sample. Data
are presented as a mean ± standard deviation from three aggregates per group (n = 3). *P <0.05.
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IGF-1 has also been shown to improve chondrogenesis
by increasing COL II and AGC expression when given
in combination with TGF-b1, bone morphogenic pro-
tein-6 and TGF-b3 [12,37,38], but when administered
alone is not sufficiently inductive in MSCs [39-41] or in
ASCs, where exogenous protein was necessary in greater
doses [42]. Our results show that IGF-1 not only stimu-
lates the expression of chondrogenic markers, but also
stimulates the expression of COL × in all the experi-
mental groups in which it was tested. In monolayer cul-
tures, FGF-2 increases cell proliferation, enhances the
chondrogenic potential of MSCs, stabilizes phenotypic
expression, and restrains terminal chondrocyte differen-
tiation [43]. Mitogenic properties on in vitro articular
chondrocytes have also been attributed to FGF-2.
Enhancement of cartilage repair has been observed fol-
lowing the application of recombinant FGF-2 protein
[44], transfected chondrocytes [45], or direct in gene
transfer in vivo experiments using adeno-associated
virus vectors into joint cartilage defects [46].
Our results show that FGF-2 not only stimulates the
expression of chondrogenic markers, but also restrains
the expression of COL I in all the experimental groups
in which it was tested. A recent study has shown that
combined overexpression of IGF-1 and FGF-2 within
cartilage defects in alginate-embedded NIH 3T3 cells
significantly enhances the repair of full-thickness osteo-
chondral cartilage defects when compared with IGF-1
stimulation alone [13]. The study concluded that these
two factors complement each other because FGF-2
enhances early chondrogenesis, whereas IGF-1 exerts its
effects on chondrocyte proliferation and matrix synth-
esis at later time points. Despite the findings of this and
other similar reports [47], the clear mechanism for
chondrocyte differentiation exerted by IGF-1 and FGF-2
remains unclear. In our study, mRNA analyses for
selected chondrocyte differentiation targets showed that
aggregate culture with IGF-1 maintained high transcrip-
tion of AGC, BGC, CM, PGC and COL II, but also
showed a markedly significant maintained high expres-
sion for COL I and COL X. Cultured aggregates trans-
duced with FGF-2 showed increased expression of BGC,
CM, PGC and COL II, but decreased production of COL
I and COL × through time. The aggregates receiving
FGF-2 and IGF-1 showed significant earlier transcription
of AGC, BGC, CM, PGC and COL II compared with the
positive control, and expression of these markers was
sustained at high levels at all time points, with most nota-
ble differences at day 28. Even though the aggregates
transduced with Ad.FGF-2/Ad.IGF-1 also expressed COL
I at day 3, expression of this protein decreased steadily
thereafter and showed a nadir at day 28. In this group
(Ad.IGF-1/Ad.FGF-2), the behavior of mRNA of COL ×
was very similar to the positive control with only greater
expression at day 14 of culture.
The negative control group used in the gene expres-
sion analysis (Figure 1) showed endogenous basal
expression for both the transduced genes (IGF-1, TGF-
b1, FGF-2 and SOX9) and the cartilage-specific marker
genes. Since cells in this group were cultured in incom-
plete chondrogenic medium without the induction of
growth factors for 28 days, we assume that basal expres-
sion of these genes reflects their role in cell prolifera-
tion, survival, and involvement in an undetermined
nonchondrogenic differentiation process.
Immunohistologic and western blot studies for this same
experimental group of treatment resemble the mRNA
expression behavior and clarify that there is an optimal
production of COL II in 28-day cultured aggregates, while
the presence of COL × and COL I is scarce and undetect-
able, respectively. There are suggestions that the expres-
sion of COL × should be considered with some caution;
this protein has been regarded as a marker of hypertrophic
differentiation, but Mwale and colleagues reported that
COL × is expressed early during the process of chondro-
genesis, even anticipating the production of COL II [48].
In conclusion, we demonstrate that a combination of IGF-
1 and FGF-2 increases cell proliferation, GAG and col-
lagen deposition, and renders acceptable results to create a
predifferentiated implant of gene-modified ASC amenable
for preclinical studies in the ovine model.
Limitations to this study include the use of only one
sheep for experimental trials, which also was young, giving
it greater regenerative capacity than older animals, and
that this feature possible may mask the real functional
contribution of the transduced genes in the chondrogenic
differentiation capacity of ASCs. Additional analyses of
combinations of selected factors not tested in this study
are desirable to define the best transduction conditions for
cartilage differentiation of ASCs, but the combination of
IGF-1 and FGF-2 is amenable to starting preclinical stu-
dies in large animal models. These findings support the
concept of implementing this gene transfer strategies for
future research in articular cartilage repair.
Conclusion
This study reports the enhanced chondrogenic differen-
tiation of ASCs as a result of synergistically effect of
combined overexpression of IGF-1/FGF-2 within ASCs
by delivery adenoviral gene transfer, supported by ana-
lyses of gene expression, histological and biochemical as
compared with the transduction of other known chon-
drogenic factors and transcriptions signals. We also
found that this combination promotes significant pro-
duction of COL II and other molecules involved in car-
tilage production (AGC, BGC, CM, and PGC), while it
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restrains the expression of COL I and COL X. The IGF-
1/FGF-2 combination is amenable to generate an in
vitro graft material for preclinical assays in large mam-
malian animal models for cartilage repair.
Additional material
Additional File 1: table describing the primers used in the qRT-PCR
analysis using the iScript™™ One Step RT-PCR Kit with SYBR®® Green
(Bio-Rad). F, forward (sense) primer; R, reverse (anti-sense) primer.
Additional File 2: figure showing ASC viability with single and
combined adenoviral transduction. Monolayers were transduced with
increasing doses of Ad.GFP, Ad.IGF-1, Ad.TGF-b1, Ad.FGF-2 and Ad.SOX9
(A) alone and (B) in combination. At 10 days, cell viability was measured
with the Alamar Blue assay; the optical density OD570 to 600 nm values of
untransduced cells were set as 100%. Data expressed as mean standard
error of triplicate experiments. (C) At 72 hours, GFP-positive cells were
counted in three fields under light and fluorescence microscopy. Results
are presented as the mean percentage of fluorescent cells per field at
each viral dose. (D) Representative fluorescence of ASCs transduced with
1, 10, 100, and 1,000 MOIs of Ad.GFP, as indicated.
Additional File 3: figure showing Protein expression from ASC
aggregates after adenoviral-mediated gene transfer of IGF-1 and
FGF-2 alone and in combination. Values represent levels of protein
product (pg/ml) in (A,B,C) the conditioned medium at days 3, 7, 14, and
21, and (D,E,F) the aggregates at days 14 and 28. ASC aggregates singly
infected with (A,D) Ad.IGF-1, (B,E) Ad.FGF-2, or (C,F) infected dually with
Ad.IGF-1 at 50 MOIs and Ad.FGF-2 at 50 MOIs (100 MOIs together). Data
represented as means standard deviations of three pellets per condition.
Abbreviations
AGC: aggrecan; ASC: adipose-derived stem cell; BGC: biglycan; BSA: bovine
serum albumin; CM: cartilage matrix; COL I: collagen I; COL II: collagen II;
COL X: collagen X; DMEM: Dulbecco’s modified Eagle’s medium; ELISA:
enzyme-linked immunosorbent assay; FBS: fetal bovine serum; FGF-2:
fibroblast growth factor-2; GAG: glycosaminoglycan; GAPDH: glyceraldehyde-
3-phosphate dehydrogenase; GFP: green fluorescent protein; IGF-1: insulin-
like growth factor-1; mAb: monoclonal antibody; MOI: multiplicity of
infection; MSC: mesenchymal stem cells; PBS: phosphate-buffered saline; PCR:
polymerase chain reaction; PGC: proteoglycan; qRT: quantitative real time;
RT: reverse transcriptase; SOX9: sex-determining region Y-box 9; TGFβ:
transforming growth factor beta.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IG-V carried out the isolation, culture, characterization and transduction of
ASCs, qRT-PCR, biochemical assays, and statistical analysis. MG-R also
participated in the qRT-PCR analyses. VJR-D and MAE-J carried out the
histological and immunohistochemical analysis. IG-V and MLM-F carried out
the construction of the recombinant adenoviral vectors and drafted the
manuscript. IAM-M and DAB-G carried out the western blot and
densitometry analysis. HGM-R and RO-L were involved in the design of the
study and reviewed the manuscript. AR-M conceived of the study, and
participated in its design and coordination and helped to draft the
manuscript. The authors are responsible for the content and writing of this
research paper. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by CONACYT through the approved grant (SSA/
IMSS/ISSSTE-CONACYT-112606-2009).
Authors’ details
1Departamento de Bioquimica y Medicina Molecular, Facultad de Medicina,
Universidad Autonoma de Nuevo Leon, Monterrey C.P. 64460, Mexico.
2Laboratorio de Medicina Molecular, Unidad Academica de Medicina
Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas,
Zacatecas, C.P 98160 Mexico. 3Departamento de Histologia, Facultad de
Medicina, Universidad Autonoma de Nuevo Leon, Monterrey C.P. 64460,
Mexico. 4Unidad de Terapia Genica y Celular, Centro de Investigación y
Desarrollo en Ciencias de la Salud, Universidad Autonoma de Nuevo Leon,
Monterrey C.P. 64460, Mexico.
Received: 6 April 2012 Revised: 23 October 2012
Accepted: 30 July 2013 Published: 30 July 2013
References
1. Beris AE, Lykissas MG, Papageorgiou CD, Georgoulis AD: Advances in
articular cartilage repair. Injury 2005, 36(Suppl 4):S14-S23.
2. Bedi A, Feeley BT, Williams RJ: Management of articular cartilage defects
of the knee. J Bone Joint Surg Am 2010, 92:994-1009.
3. Thirion S, Berenbaum F: Culture and phenotyping of chondrocytes in
primary culture. Methods Mol Med 2004, 100:1-14.
4. Stokes DG, Liu G, Coimbra IB, Piera-Velazquez S, Crowl RM, Jimenez SA:
Assessment of the gene expression profile of differentiated and
dedifferentiated human fetal chondrocytes by microarray analysis.
Arthritis Rheum 2002, 46:404-419.
5. Wei Y, Sun X, Wang W, Hu Y: Adipose-derived stem cells and
chondrogenesis. Cytotherapy 2007, 9:712-716.
6. Ronziere MC, Perrier E, Mallein-Gerin F, Freyria AM: Chondrogenic potential
of bone marrow- and adipose tissue-derived adult human mesenchymal
stem cells. Biomed Mater Eng 2010, 20:145-158.
7. Estes BT, Wu AW, Storms RW, Guilak F: Extended passaging, but not
aldehyde dehydrogenase activity, increases the chondrogenic potential
of human adipose-derived adult stem cells. J Cell Physiol 2006,
209:987-995.
8. Peterson B, Zhang J, Iglesias R, Kabo M, Hedrick M, Benhaim P,
Lieberman JR: Healing of critically sized femoral defects, using
genetically modified mesenchymal stem cells from human adipose
tissue. Tissue Eng 2005, 11:120-129.
9. Steinert AF, Ghivizzani SC, Rethwilm A, Tuan RS, Evans CH, Noth U: Major
biological obstacles for persistent cell-based regeneration of articular
cartilage. Arthritis Res Ther 2007, 9:213.
10. Yan J, Li L, Zhang Q: [In vitro study on induction systems for marrow
mesenchymal stem cells to chondrocytes]. Zhongguo Xiu Fu Chong Jian
Wai Ke Za Zhi 2006, 20:1114-1118.
11. Park H, Temenoff JS, Tabata Y, Caplan AI, Raphael RM, Jansen JA, Mikos AG:
Effect of dual growth factor delivery on chondrogenic differentiation of
rabbit marrow mesenchymal stem cells encapsulated in injectable
hydrogel composites. J Biomed Mater Res A 2009, 88:889-897.
12. Fukumoto T, Sperling JW, Sanyal A, Fitzsimmons JS, Reinholz GG,
Conover CA, O’Driscoll SW: Combined effects of insulin-like growth
factor-1 and transforming growth factor-β1 on periosteal mesenchymal
cells during chondrogenesis in vitro. Osteoarthritis Cartilage 2003, 11:55-64.
13. Madry H, Orth P, Kaul G, Zurakowski D, Menger MD, Kohn D, Cucchiarini M:
Acceleration of articular cartilage repair by combined gene transfer of
human insulin-like growth factor I and fibroblast growth factor-2 in vivo.
Arch Orthop Trauma Surg 2010, 130:1311-1322.
14. Stevens MM, Marini RP, Martin I, Langer R, Prasad Shastri V: FGF-2
enhances TGF-β1-induced periosteal chondrogenesis. J Orthop Res 2004,
22:1114-1119.
15. Lefebvre V, Behringer RR, de Crombrugghe B: L-Sox5, Sox6 and Sox9
control essential steps of the chondrocyte differentiation pathway.
Osteoarthritis Cartilage 2001, 9(Suppl A):S69-S75.
16. Trippel SB, Ghivizzani SC, Nixon AJ: Gene-based approaches for the repair
of articular cartilage. Gene Ther 2004, 11:351-359.
17. Grande DA, Mason J, Light E, Dines D: Stem cells as platforms for delivery
of genes to enhance cartilage repair. J Bone Joint Surg Am 2003,
85-A(Suppl 2):111-116.
18. Ghivizzani SC, Oligino TJ, Glorioso JC, Robbins PD, Evans CH: Direct gene
delivery strategies for the treatment of rheumatoid arthritis. Drug Discov
Today 2001, 6:259-267.
19. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH,
Haydon RC, Kinzler KW, Vogelstein B, He TC: A protocol for rapid
generation of recombinant adenoviruses using the AdEasy system. Nat
Protoc 2007, 2:1236-1247.
Garza-Veloz et al. Arthritis Research & Therapy 2013, 15:R80
http://arthritis-research.com/content/15/4/R80
Page 12 of 13
20. Dubois SG, Floyd EZ, Zvonic S, Kilroy G, Wu X, Carling S, Halvorsen YD,
Ravussin E, Gimble JM: Isolation of human adipose-derived stem cells
from biopsies and liposuction specimens. Methods Mol Biol 2008,
449:69-79.
21. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25:402-408.
22. Reger RL, Tucker AH, Wolfe MR: Differentiation and characterization of
human MSCs. Methods Mol Biol 2008, 449:93-107.
23. Lee RH, Kim B, Choi I, Kim H, Choi HS, Suh K, Bae YC, Jung JS:
Characterization and expression analysis of mesenchymal stem cells
from human bone marrow and adipose tissue. Cell Physiol Biochem 2004,
14:311-324.
24. Estes BT, Diekman BO, Gimble JM, Guilak F: Isolation of adipose-derived
stem cells and their induction to a chondrogenic phenotype. Nat Protoc
2010, 5:1294-1311.
25. Cao L, Yang F, Liu G, Yu D, Li H, Fan Q, Gan Y, Tang T, Dai K: The
promotion of cartilage defect repair using adenovirus mediated Sox9
gene transfer of rabbit bone marrow mesenchymal stem cells.
Biomaterials 2011, 32:3910-3920.
26. Jin X, Sun Y, Zhang K, Wang J, Shi T, Ju X, Lou S: Ectopic neocartilage
formation from predifferentiated human adipose derived stem cells
induced by adenoviral-mediated transfer of hTGF β2. Biomaterials 2007,
28:2994-3003.
27. Gelse K, von der Mark K, Aigner T, Park J, Schneider H: Articular cartilage
repair by gene therapy using growth factor-producing mesenchymal
cells. Arthritis Rheum 2003, 48:430-441.
28. Pagnotto MR, Wang Z, Karpie JC, Ferretti M, Xiao X, Chu CR: Adeno-
associated viral gene transfer of transforming growth factor-beta1 to
human mesenchymal stem cells improves cartilage repair. Gene Ther
2007, 14:804-813.
29. Hu G, Liu P, Feng J, Jin Y: A novel population of mesenchymal
progenitors with hematopoietic potential originated from CD14
peripheral blood mononuclear cells. Int J Med Sci 2010, 8:16-29.
30. Pittenger MF: Mesenchymal stem cells from adult bone marrow. Methods
Mol Biol 2008, 449:27-44.
31. Munirah S, Samsudin OC, Aminuddin BS, Ruszymah BH: Expansion of
human articular chondrocytes and formation of tissue-engineered
cartilage: a step towards exploring a potential use of matrix-induced cell
therapy. Tissue Cell 2010, 42:282-292.
32. Yaeger PC, Masi TL, de Ortiz JL, Binette F, Tubo R, McPherson JM:
Synergistic action of transforming growth factor-beta and insulin-like
growth factor-I induces expression of type II collagen and aggrecan
genes in adult human articular chondrocytes. Exp Cell Res 1997,
237:318-325.
33. Mehlhorn AT, Niemeyer P, Kaiser S, Finkenzeller G, Stark GB, Sudkamp NP,
Schmal H: Differential expression pattern of extracellular matrix
molecules during chondrogenesis of mesenchymal stem cells from bone
marrow and adipose tissue. Tissue Eng 2006, 12:2853-2862.
34. Barry F, Boynton RE, Liu B, Murphy JM: Chondrogenic differentiation of
mesenchymal stem cells from bone marrow: differentiation-dependent
gene expression of matrix components. Exp Cell Res 2001, 268:189-200.
35. Martin JA, Scherb MB, Lembke LA, Buckwalter JA: Damage control
mechanisms in articular cartilage: the role of the insulin-like growth
factor I axis. Iowa Orthop J 2000, 20:1-10.
36. Patil AS, Sable RB, Kothari RM: Role of insulin-like growth factors (IGFs),
their receptors and genetic regulation in the chondrogenesis and
growth of the mandibular condylar cartilage. J Cell Physiol 2012,
227:1796-1804.
37. Khan WS, Adesida AB, Tew SR, Lowe ET, Hardingham TE: Bone marrow-
derived mesenchymal stem cells express the pericyte marker 3G5 in
culture and show enhanced chondrogenesis in hypoxic conditions.
J Orthop Res 2010, 28:834-840.
38. Indrawattana N, Chen G, Tadokoro M, Shann LH, Ohgushi H, Tateishi T,
Tanaka J, Bunyaratvej A: Growth factor combination for chondrogenic
induction from human mesenchymal stem cell. Biochem Biophys Res
Commun 2004, 320:914-919.
39. Palmer GD, Steinert A, Pascher A, Gouze E, Gouze JN, Betz O, Johnstone B,
Evans CH, Ghivizzani SC: Gene-induced chondrogenesis of primary
mesenchymal stem cells in vitro. Mol Ther 2005, 12:219-228.
40. Kawamura K, Chu CR, Sobajima S, Robbins PD, Fu FH, Izzo NJ, Niyibizi C:
Adenoviral-mediated transfer of TGF-β1 but not IGF-1 induces
chondrogenic differentiation of human mesenchymal stem cells in
pellet cultures. Exp Hematol 2005, 33:865-872.
41. Weiss S, Hennig T, Bock R, Steck E, Richter W: Impact of growth factors
and PTHrP on early and late chondrogenic differentiation of human
mesenchymal stem cells. J Cell Physiol 2010, 223:84-93.
42. Kim HJ, Im GI: Chondrogenic differentiation of adipose tissue-derived
mesenchymal stem cells: greater doses of growth factor are necessary.
J Orthop Res 2009, 27:612-619.
43. Handorf AM, Li WJ: Fibroblast growth factor-2 primes human
mesenchymal stem cells for enhanced chondrogenesis. PLoS One 2011, 6:
e22887.
44. Maehara H, Sotome S, Yoshii T, Torigoe I, Kawasaki Y, Sugata Y, Yuasa M,
Hirano M, Mochizuki N, Kikuchi M, Shinomiya K, Okawa A: Repair of large
osteochondral defects in rabbits using porous hydroxyapatite/collagen
(HAp/Col) and fibroblast growth factor-2 (FGF-2). J Orthop Res 2010,
28:677-686.
45. Kaul G, Cucchiarini M, Arntzen D, Zurakowski D, Menger MD, Kohn D,
Trippel SB, Madry H: Local stimulation of articular cartilage repair by
transplantation of encapsulated chondrocytes overexpressing human
fibroblast growth factor 2 (FGF-2) in vivo. J Gene Med 2006, 8:100-111.
46. Cucchiarini M, Madry H, Ma C, Thurn T, Zurakowski D, Menger MD, Kohn D,
Trippel SB, Terwilliger EF: Improved tissue repair in articular cartilage
defects in vivo by rAAV-mediated overexpression of human fibroblast
growth factor 2. Mol Ther 2005, 12:229-238.
47. Loeser RF, Chubinskaya S, Pacione C, Im HJ: Basic fibroblast growth factor
inhibits the anabolic activity of insulin-like growth factor 1 and
osteogenic protein 1 in adult human articular chondrocytes. Arthritis
Rheum 2005, 52:3910-3917.
48. Mwale F, Stachura D, Roughley P, Antoniou J: Limitations of using
aggrecan and type × collagen as markers of chondrogenesis in
mesenchymal stem cell differentiation. J Orthop Res 2006, 24:1791-1798.
doi:10.1186/ar4260
Cite this article as: Garza-Veloz et al.: Analyses of chondrogenic
induction of adipose mesenchymal stem cells by combined co-
stimulation mediated by adenoviral gene transfer. Arthritis Research &
Therapy 2013 15:R80.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Garza-Veloz et al. Arthritis Research & Therapy 2013, 15:R80
http://arthritis-research.com/content/15/4/R80
Page 13 of 13
